Key Zealand peptide competences
Zealand is a Danish biotechnology company dedicated to the discovery, design and development of innovative peptide-based medicines. Our in-house competences include deep understanding of peptide chemistry and functionality coupled with extensive experience applying structural design principles to develop novel medicines.
Our R&D organization is structured to progress novel investigational peptide medicines effectively through preclinical development, including establishment of proof-of-mechanism in cell based disease assays (in vitro) and in key animal disease models (in vivo). In development, we have the necessary in-house capacity to advance investigational medicines from idea to preclinical IND-enabling studies and through the clinical development Phase I to III.
Our therapeutic focus
Our therapeutic focus lies in specialty disease areas where peptide-based medicines have particular relevance and where the patient populations are easily identifiable and treated by specialists. We are moreover focused on specialty disease areas where we believe the present standard of care is inadequate and where we believe that we have the resources to advance our peptide-based product candidate into the later stages of clinical development including registration and potentially commercialization.